Last Update: Feb 20, 2024
Special Drug Use-results Surveillance of Tabrecta Tablets (MET Exon 14 Skipping Mutation-positive Unresectable Advanced/Recurrent Non-small Cell Lung Cancer) Identifier:
Novartis Reference Number:CINC280AJP01
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

This study is an uncontrolled, primary data collection-based observational study to be conducted as a central registration system, multicenter special drug-use results surveillance. As an all-case study, this study will collect all patients treated with Tabrecta in a specified post-marketing period. The observation period of each patient is up to 1 year (52 weeks)

Non-small Cell Lung Cancer
Nov 02, 2020
Oct 31, 2024
- 99 Years (Child, Adult, Older Adult)



Tabrecta tablets

There is no treatment allocation. Patients administered Tabrecta by prescription that have started before inclusion of the patient into the study will be enrolled.

Eligibility Criteria

Inclusion Criteria:

All patients receiving Tabrecta for MET exon 14 skipping mutation-positive unresectable advanced/recurrent NSCLC during a specified post-marketing period

Exclusion Criteria:


Study Location

Novartis Investigative Site


Shimotsuga Gun,Tochigi,321-0293,Japan

Novartis Investigative Site


Sunto Gun,Shizuoka,411 8777,Japan

Novartis Investigative Site



Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals